Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | CCKAR | P32238 | 1/20 | 0.49 |
| ▸ | CCKBR | P32239 | 1/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.47 |
| ▸ | BRS3 | P32247 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557726 | 0.91 | BCHE (0.55) | DPP3CYP2C19BCHECCKARCCKBR | |
| SCHEMBL31198206 | 0.88 | DPP3 (0.60) | DPP3CYP2C19BCHECAPN1CTSB | |
| SCHEMBL29379873 | 0.87 | DPP4 (0.58) | DPP3CYP2C19BCHEDPP4OPRM1 | |
| SCHEMBL31127571 | 0.87 | GHSR (0.54) | DPP3BCHEGHSRNTSR2NTSR1 | |
| SCHEMBL29420134 | 0.86 | DPP3 (0.57) | DPP3CYP2C19BCHECAPN1CTSB | |
| SCHEMBL30183471 | 0.85 | CTSL (0.53) | CAPN1CTSB | |
| SCHEMBL30679613 | 0.84 | CAPN1 (0.55) | DPP3CCKARCCKBRCAPN1CTSB | |
| SCHEMBL31396846 | 0.84 | DPP3 (0.56) | DPP3CAPN1CTSBNTSR2NTSR1 | |
| SCHEMBL30051406 | 0.84 | DPP3 (0.58) | DPP3CYP2C19BCHECAPN1CTSB | |
| SCHEMBL7325826 | 0.84 | ACE (0.61) | DPP3CYP2C19BCHEDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) | 2026-03-12 | — | — | US | claimed |
| CN-118987163-A | Use of sardine peptide-containing composition for improving atopic dermatitis symptoms | 海口桥水联合科技有限责任公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024235082-A1 | USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS | 海口桥水联合科技有限责任公司 | 2024-11-21 | — | — | WO | claimed |
| CN-116350746-B | Application of sardine peptide composition in medicines for treating allergic rhinitis | 海口桥水联合科技有限责任公司 | 2024-03-22 | — | — | CN | claimed |
| CN-116350746-A | Application of sardine peptide composition in medicines for treating allergic rhinitis | 海口桥水联合科技有限责任公司 | 2023-06-30 | — | — | CN | claimed |
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) | 2026-03-12 | — | — | US | disclosed |
| CN-118987163-A | Use of sardine peptide-containing composition for improving atopic dermatitis symptoms | 海口桥水联合科技有限责任公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024235082-A1 | USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS | 海口桥水联合科技有限责任公司 | 2024-11-21 | — | — | WO | disclosed |
| CN-116350746-B | Application of sardine peptide composition in medicines for treating allergic rhinitis | 海口桥水联合科技有限责任公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-116350746-A | Application of sardine peptide composition in medicines for treating allergic rhinitis | 海口桥水联合科技有限责任公司 | 2023-06-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | VIP, ANPEP, RNPEP | DPP3 191/4885CYP2C19 373/4885BCHE 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.